Αρχική World News Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment... World News Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer Από Ogkologos - 18 Μαΐου, 2026 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR 7 images that defined cancer policy in 2022 27 Δεκεμβρίου, 2022 A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations... 20 Ιανουαρίου, 2023 Young Breast Cancer Survivor Killed in Hit and Run Crash Weeks... 25 Αυγούστου, 2021 FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller 5 Ιανουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Poherdy The American Rescue Act: What You Need to Know T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... Changes in Metabolism Help Melanomas Spread